The Sanfilippo syndrome type B (mucopolysaccharidosis IIIB) is an autosomal recessive disorder due to mutations in the gene encoding NAGLU (alpha-N-acetylglucosaminidase), one of the enzymes required for the degradation of the GAG (glycosaminoglycan) heparan sulphate. No therapy exists for affected patients. We have shown previously the efficacy of lentiviral-NAGLU-mediated gene transfer in correcting in vitro the defect on fibroblasts of patients. In the present study, we tested the therapy in vivo on a knockout mouse model using intravenous injections. Mice (8-10 weeks old) were injected with one of the lentiviral doses through the tail vein and analysed 1 month after treatment. A single injection of lentiviral-NAGLU vector resulted in transgene expression in liver, spleen, lung and heart of treated mice, with the highest level reached in liver and spleen. Expression of 1% normal NAGLU activity in liver resulted in a 77% decrease in the GAG content; more remarkably, an expression of 0.16% normal activity in lung was capable of decreasing the GAG level by 29%. Long-term (6 months) follow up of the gene therapy revealed that the viral genome integration persisted in the target tissues, although the real-time PCR analysis showed a decrease in the vector DNA content with time. Interestingly, the decrease in GAG levels was maintained in liver, spleen, lung and heart of treated mice. These results show the promising potential and the limitations of lentiviral-NAGLU vector to deliver the human NAGLU gene in vivo.

Treatment of the mouse model of mucopolysaccharidosis type IIIB with lentiviral-NAGLU vector / DI NATALE, Paola; C., DI DOMENICO; N., Gargiulo; S., Castaldo; E. GONZALEZ Y., Reyero; P., Mithbaokar; DE FELICE, Mario; A., Follenzi; L., Naldini; Villani, GUGLIELMO ROSARIO DOMENI. - In: BIOCHEMICAL JOURNAL. - ISSN 0264-6021. - STAMPA. - 388:2(2005), pp. 639-646. [10.1042/BJ20041702]

Treatment of the mouse model of mucopolysaccharidosis type IIIB with lentiviral-NAGLU vector

DI NATALE, PAOLA;DE FELICE, MARIO;VILLANI, GUGLIELMO ROSARIO DOMENI
2005

Abstract

The Sanfilippo syndrome type B (mucopolysaccharidosis IIIB) is an autosomal recessive disorder due to mutations in the gene encoding NAGLU (alpha-N-acetylglucosaminidase), one of the enzymes required for the degradation of the GAG (glycosaminoglycan) heparan sulphate. No therapy exists for affected patients. We have shown previously the efficacy of lentiviral-NAGLU-mediated gene transfer in correcting in vitro the defect on fibroblasts of patients. In the present study, we tested the therapy in vivo on a knockout mouse model using intravenous injections. Mice (8-10 weeks old) were injected with one of the lentiviral doses through the tail vein and analysed 1 month after treatment. A single injection of lentiviral-NAGLU vector resulted in transgene expression in liver, spleen, lung and heart of treated mice, with the highest level reached in liver and spleen. Expression of 1% normal NAGLU activity in liver resulted in a 77% decrease in the GAG content; more remarkably, an expression of 0.16% normal activity in lung was capable of decreasing the GAG level by 29%. Long-term (6 months) follow up of the gene therapy revealed that the viral genome integration persisted in the target tissues, although the real-time PCR analysis showed a decrease in the vector DNA content with time. Interestingly, the decrease in GAG levels was maintained in liver, spleen, lung and heart of treated mice. These results show the promising potential and the limitations of lentiviral-NAGLU vector to deliver the human NAGLU gene in vivo.
2005
Treatment of the mouse model of mucopolysaccharidosis type IIIB with lentiviral-NAGLU vector / DI NATALE, Paola; C., DI DOMENICO; N., Gargiulo; S., Castaldo; E. GONZALEZ Y., Reyero; P., Mithbaokar; DE FELICE, Mario; A., Follenzi; L., Naldini; Villani, GUGLIELMO ROSARIO DOMENI. - In: BIOCHEMICAL JOURNAL. - ISSN 0264-6021. - STAMPA. - 388:2(2005), pp. 639-646. [10.1042/BJ20041702]
File in questo prodotto:
File Dimensione Formato  
3 Biochem J 2005.pdf

non disponibili

Tipologia: Documento in Post-print
Licenza: Accesso privato/ristretto
Dimensione 413.15 kB
Formato Adobe PDF
413.15 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/202179
Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 49
  • ???jsp.display-item.citation.isi??? ND
social impact